TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01129141

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tele-PTM
Description: Telephone-based Progressive Tinnitus Management (Tele-PTM) is a novel home-based telehealth program that involves a series of seven telephone appointments, conducted at approximately 1, 2, 3, 4, and 5 weeks, and 3 and 6 months after enrollment is finalized. Telephone education was provided by the Study Psychologist at weeks 1, 3, and 5, and month 6; and by the Study Audiologist at weeks 2 and 4, and month 3.
Study: NCT00318890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel is given at a dose of 75 mg/m2 intravenously on Days 1, 21, and 43 and continued at variable doses for 4 weeks with standard radiotherapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiation therapy will be given 5 days each week for 4 weeks plus a concomitant boost in the last 2 weeks of treatment to deliver 54 Gy in 30 fractions. Radiotherapy will follow the induction chemotherapy with docetaxel and cisplatin.
Study: NCT01129141

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Wait List Control
Description: Wait List Control subjects received Tele-PTM after completing the 6-month questionnaires. Participants assigned to Wait List Control were instructed that they could receive any available tinnitus services, and that they would receive Tele-PTM following completion of the 3- and 6-month questionnaires.
Study: NCT02994862

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Galla Chinnesis
Description: new Remineralizing Agent before Bonding to teeth with amelogenesis imperfecta

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Bonding
Description: Normal Bonding Protocol
Study: NCT03761732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Islamic Trauma Healing
Description: 6 session behavioral intervention program designed to reduce PTSD and related symptomatology
Study: NCT04292730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Administered as an intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Administered as an intravenous infusion
Study: NCT02861716

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight plus dexmedetomidine 0.2 μg/kg in 2ml volume and it will be injected slowly over 20 seconds.
Study: NCT03921775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosilate
Description: For induction and maintenance of general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: For induction and maintenance of general anesthesia
Study: NCT00545922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Seven weekly sessions (2 hrs) in groups

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Telephone Contact
Description: Telephone contact (max. 10 minutes) every other week during the 7-week intervention
Study: NCT02256553

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-3641 12 Amb a 1-U (short ragweed extract)
Description: 12 units of Ambrosia artemisiifolia major allergen number 1 (Amb a 1-U) extract sublingual tablets

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-7243 2800 BAU (Timothy grass extract)
Description: 2800 bioequivalent allergen units (BAU) of Phleum pratense extract sublingual tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue Medication
Description: Self-injectable epinephrine, to be administered for an anaphylactic reaction, including symptoms/signs of upper airway obstruction.
Study: NCT01714479

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Leucine-enriched nutritional supplement
Description: A protein and carbohydrate supplement with high levels of leucine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leucine-enriched nutritional supplement
Description: A protein and carbohydrate supplement with high levels of leucine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03384342

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narrow-band UV-B therapy
Description: * Patients treated with NBUVB and showed 75% or more repigmentation rate would be included.~* For a total period of 12 months, narrow-band UV-B therapy is performed once a month.
Study: NCT04371029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PSG
Description: Polysomnography at 3 times, actimetry measure and Pittsburgh questionnaire
Study: NCT02292056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1-on-1 counseling
Description: 1. Precounseling questionnaire collecting demographic information, contraception information, and reasons for choosing contraceptive method~2. Precounseling quiz: assess baseline level of knowledge regarding medication safety and contraceptive option.~3. Counseling: completed by MotherToBaby counselor about the safety of their medications for use in pregnancy.~4. 10 minute video entitled The Contraceptive Choice Project: Which Birth Control Method is Right for You? by Washington University in St. Louis.~5. Post-Counseling Quiz to assess whether specialized training impacted their understanding of medication safety and contraceptive options.~6. Post-Counseling Questionnaire: assess contraceptive plans and satisfaction with counseling
Study: NCT03426709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low intensity Internet-delivered psychotherapy
Description: The online intervention will be individual and interactive, which will be supported by multimedia material (videos, sound recordings, etc.) and will have internet support. The estimated duration of the program is 8 weeks. Low Intensity Internet-delivered psychotherapy: Psychoeducation, Healthy living habits, Behavioral activation, Positive Psychology, Mindfulness and Compassion
Study: NCT02344706

Intervention type: DEVICE
Intervention: Registration of EEG
Description: EEG is registered for study purposes. No interventions to patient care is done at this stage. Acquisition is done without harming the patient.
Study: NCT04653987

Intervention type: PROCEDURE
Intervention: Percutaneous biliary drainage

Intervention type: PROCEDURE
Intervention: Percutaneous biliary drainage
Study: NCT02782273

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: The patients randomised to this arm they will receive 30 mg intravenous ketorolac.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: The patients randomised to this arm they will receive 0,1 mg/kg intravenous morphine.
Study: NCT04153994

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Blockade
Description: The ESPB is fascial plane block performed by injecting local anesthetic between the erector spinae muscle and the transverse process. Its proposed mechanism of action is via blockade of the dorsal and ventral rami of the thoracic spinal nerves and sympathetic fibers.
Study: NCT03386344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Pharmaceutical form: Tablet; Route of administration: Oral
Study: NCT00318890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine
Description: Amifostine will be administered as a subcutaneous injection on a daily basis during radiotherapy.
Study: NCT00596791

Intervention type: DRUG
Group type: OTHER
Intervention: tafluprost
Description: prostaglandine analoque
Study: NCT04136314

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision-Framed Survey
Description: Survey will ask all subjects for will be asked to indicate basic demographic information, such as age, sex, race, and education level. Also, subjects will indicate whether they have been diagnosed with psoriatic arthritis. Importantly, patients will complete the survey questions anonymously, and no direct patient identifiers or HIPPA-protected information will be collected. Subjects will then be asked to indicate their preference for a hypothetical injectable medication after exposure to \[A\] a gain-framed message or \[B\] a loss-framed message.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision-Framed Survey
Description: Survey will ask all subjects for will be asked to indicate basic demographic information, such as age, sex, race, and education level. Also, subjects will indicate whether they have been diagnosed with psoriatic arthritis. Importantly, patients will complete the survey questions anonymously, and no direct patient identifiers or HIPPA-protected information will be collected. Subjects will then be asked to indicate their preference for a hypothetical injectable medication after exposure to \[A\] a gain-framed message or \[B\] a loss-framed message.
Study: NCT04292730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Administered as an intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care Treatment for COVID-19 Infection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care Treatment for COVID-19 Infection
Study: NCT03386344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Pharmaceutical form: Tablet; Route of administration: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Tablet; Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: Tablet; Route of administration: Oral
Study: NCT01016275

Intervention type: DEVICE
Intervention: Misago (stent placement)
Description: Misago iliac stent
Study: NCT01952002

Intervention type: OTHER
Intervention: Inspiratory Muscle Training
Description: Each session The session itself consisted of the following: two sets of 15 breathe cycles without removing the breathing promoter from the mouth and with the aid of a nose clip and 1-minute interval between sets. For training, we used the breathing promoters Power Breathe® Plus Light and Medium Resistance, possessing 10 levels of load gradation ranging from 17 to 186 cm H2O, which were adjusted for each patient and allowed for the individualized prescription of IMT
Study: NCT03249961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham TDCS
Description: Placebo stimulation is applied to the left motor cortex while participants perform a motor task in the right hand. During the motor task, participants use their right hand to pinch a force transducer that controls an on-screen cursor to navigate between a start position and a sequence of 5 other positions to the right.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal TDCS
Description: Excitatory stimulation is applied to the left motor cortex while participants perform a motor task in the right hand. During the motor task, participants use their right hand to pinch a force transducer that controls an on-screen cursor to navigate between a start position and a sequence of 5 other positions to the right.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Participants will receive Transcranial Magnetic Stimulation (TMS) to allow research investigators to determine the location of the left motor cortex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Participants will receive Transcranial Magnetic Stimulation (TMS) to allow research investigators to determine the location of the left motor cortex.
Study: NCT01940913

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic capsules
Study: NCT00814762

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV Vaccine 732462
Description: Two doses reconstituted adjuvanted vaccine, injected intramuscularly, at an interval of approximately one month.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaccine
Description: Two doses of placebo, injected intramuscularly, at an interval of approximately one month
Study: NCT04254926

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Revie ⊕
Description: Revie ⊕ is a positive approach centered on the resources and strengths of the patient, and it consists of an intervention that focuses on the individual's life review. Revie ⊕ allows specialist nurses to discuss life events with cancer patients, to identify the significant elements, and to explore how the diagnosis has changed their values and preferences. The intervention is geared toward working with the patient to discover their potential, to identify their strategies for coping with the events of their life, and to thereby accompany them in achieving a better understanding of themselves and what defines their identity. The intervention also allows their concerns surrounding death to be addressed, in addition to providing clarity in regard to the life projects. In the end, as a conclusion to the intervention, the patient is provided a booklet recounting the salient features of their life review along with photographs, quotes, or images.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Revie ⊕
Description: Revie ⊕ is a positive approach centered on the resources and strengths of the patient, and it consists of an intervention that focuses on the individual's life review. Revie ⊕ allows specialist nurses to discuss life events with cancer patients, to identify the significant elements, and to explore how the diagnosis has changed their values and preferences. The intervention is geared toward working with the patient to discover their potential, to identify their strategies for coping with the events of their life, and to thereby accompany them in achieving a better understanding of themselves and what defines their identity. The intervention also allows their concerns surrounding death to be addressed, in addition to providing clarity in regard to the life projects. In the end, as a conclusion to the intervention, the patient is provided a booklet recounting the salient features of their life review along with photographs, quotes, or images.
Study: NCT03444129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy eating workshop and interactive health game
Description: The intervention sessions will be weekly for 6 weeks and will involve participation in health education workshop and interactive health game. Sessions may last up to 2 hours and will be held at designated times/days at a Chicago Church.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy eating workshop
Description: The intervention sessions will be weekly for 6 weeks and will involve participation in health education workshop. Sessions may last up to 2 hours and will be held at designated times/days at a Chicago Church.
Study: NCT01940913

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Study: NCT02443532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured group education
Description: The group intervention consists of interactive sessions for groups of 5-7 patients, dealing with different aspects of management of type 1 diabetes: insulin therapy and hypoglycemia, management of insulin doses, diet, physical exercise, sick days, etc. The intervention is designed for the acquisition of specific skills of self-management. This intervention is provided by a team including physicians, dietitians, and nurses.
Study: NCT02696213

Intervention type: OTHER
Group type: OTHER
Intervention: Systematic, Comprehensive, One to One Training (SCOOT)
Description: An occupational therapist trained by the principal investigator will perform 1.5 hour SCOOT sessions with participants one to two times a week over a period of 6 weeks. SCOOT will provide instruction and practice for performing scooter skills (i.e., instruction on driving, basic and advanced scooter skills) that are embedded in self-selected activities that participants want to perform using their scooters.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systematic, Comprehensive, One to One Training (SCOOT)
Description: An occupational therapist trained by the principal investigator will perform 1.5 hour SCOOT sessions with participants one to two times a week over a period of 6 weeks. SCOOT will provide instruction and practice for performing scooter skills (i.e., instruction on driving, basic and advanced scooter skills) that are embedded in self-selected activities that participants want to perform using their scooters.

Intervention type: OTHER
Group type: OTHER
Intervention: Six Week Delay
Description: Participants will begin the SCOOT intervention after a six week delay.
Study: NCT03177928

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transthorathic echocardiogram
Description: In echocardiography lab and using transthoracic echocardiogram to reveal any cardiac changes in patients.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transthorathic echocardiogram
Description: In echocardiography lab and using transthoracic echocardiogram to reveal any cardiac changes in patients.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transthorathic echocardiogram
Description: In echocardiography lab and using transthoracic echocardiogram to reveal any cardiac changes in patients.
Study: NCT01332383

Intervention type: DRUG
Intervention: Naratriptan
Study: NCT02843841

Intervention type: OTHER
Group type: OTHER
Intervention: Blood and fecal sample.
Description: Blood (28 ml) and fecal sample at day 0, 4 days, 3 months and one year after transplantation

Intervention type: OTHER
Group type: OTHER
Intervention: Blood and fecal sample.
Description: Blood (28 ml) and fecal sample at day 0, 4 days, 3 months and one year after transplantation
Study: NCT01668225

Intervention type: PROCEDURE
Intervention: Blood test
Description: Taking blood sample of the patient during the day 3, triggering day, oocyte collection day and pregnancy test day.~Taking the follicular fluid during the oocyte collection day
Study: NCT04373928

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drug guided by Mini-PDX/PDX
Description: Chemotherapeutic agents guided by Mini-PDX/PDX will be applied to PC patients and the efficiency will be studied.
Study: NCT03906539

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin 10mg
Description: Atorvastatin 10 mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10mg
Description: Atorvastatin 10 mg per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Virgin Coconut Oil (VCO)
Description: Capsule VCO (1000 mg/day)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule - 1 capsule per day
Study: NCT03009799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iota-Carrageenan
Description: One drop in each eye 8 times per day for 7 days (mandatory), then 4 to 8 times/day for the next 14 days until Day 21

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carmellose
Description: 1 drop in each eye 8 times/day for 7 days (mandatory), then 4 to 8 times/day for the next 14 days until day 21
Study: NCT03357562

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lung MRI
Description: lung MRI without contrast injection
Study: NCT02557737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance, Ultrasonography direct-guidance, Electric stimulation and Surface anatomy landmark.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance, Ultrasonography direct-guidance, Electric stimulation and Surface anatomy landmark.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance, Ultrasonography direct-guidance, Electric stimulation and Surface anatomy landmark.
Study: NCT02649556

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: THS 2.2
Description: Ad libitum use of THS 2.2 in an ambulatory setting for 26 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CC
Description: Ad libitum use of CC in an ambulatory setting for 26 weeks.~The subject's own preferred brands of CC (no brand restriction) continue to be used as the reference product.
Study: NCT02285387

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rhythm control
Description: 1. Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation~2. Cardioversion after 1 month~3. Rhythm FU schedule (2012 ACC/AHA/ESC guidelines)~4. If AF recur, RFCA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rate control
Description: 1. No AAD, just anticoagulation~2. HR control between 60\~110bpm (with beta blocker, calcium channel blocker, digoxin)~3. Without the treatment about antiarrhythmia and rhythm control, deification of rate control, the subject will be drop out for study.
Study: NCT04618744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORMD-0801 (Insulin) capsule 8 mg BD
Description: 8 mg ORMD-0801, 1 capsule, twice a day, once in the morning and once in the evening.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT02709330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lunasin Regimen
Description: LunaRich X Capsules, Reliv Now, ProVantage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Historical control
Description: Matched historical controls will be identified from the PatientsLikeMe database.
Study: NCT04241484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Piezowave 2
Description: Piezowave Myofascial Acoustic Compression Therapy (MyACT), which provides mechanical stimuli delivery to improve circulation and provide relief of pain. The focused sound waves produced by the Piezowave MyACT device are classified by a pressure surge, which is followed by a drop in pressure and a brief negative pressure phase low energy/low pressure application. It is this transformation of mechanical stimuli into biochemical signals, or mechanotransduction, which yields the treatment of myofascial and musculoskeletal pain